glp 1 medications tirzepatide How GLP-1 are transforming diabetes and weight loss treatment Weighing benefits, risks of GLP-1

Tumor cell responses to a novel glutathione S -transferase-activated nitric oxide-releasing prodrug

Review the assignee and co-assignee structure: does the CDMO own the patents outright, or do co-development arrangements mean a sponsors IP might be entangled with a third partys estate

It's a 'maybe,' wrapped in a 'it depends.' And what it depends on is precisely what we're going to unpack here, drawing from our team's extensive experience with high-purity peptides and their intricate mechanisms

TSGIT: an N- and C-terminal tandem tag system for purification of native and intein-mediated ligation-ready proteins

World Journal of Gastroenterology, 27 (45), 77847791